title: [Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].
abstract: OBJECTIVE
  The management of recurrent ovarian cancer is based on intravenous chemotherapy with or without debulking surgery. The hyperthermic intraperitoneal chemotherapy (HIPEC) is sometimes proposed as a complement to complete surgery. The purpose of this study was to evaluate the feasibility, morbidity and survival of HIPEC associated with complete surgical cytoreduction in the management of patients with a first recurrence of ovarian cancer.
  
  
  METHODS
  Between 2005 and 2010, 27 patients underwent surgery for a recurrence of ovarian cancer. Among them, 17 patients (63%) have received HIPEC.
  
  
  RESULTS
  Sixteen patients (94%) were completely resected after surgery. No patient died postoperatively. Two patients had intraoperative complications: a bladder injury and a section of the ureter. Eight patients had postoperative complications including 3 grade 3 or higher (two organ failure and one reoperation). Fifteen patients had a recurrence with a median DFS of 11.9 months (95% CI [5.4-32.9]) from the HIPEC. The median overall survival from diagnosis was 107.8 months.
  
  
  CONCLUSIONS
  These results showed that the association of HIPEC with a complete cytoreduction for recurrent ovarian cancer presents acceptable morbidity and survival. The results of the ongoing French multicenter study (CHIPOR) are expected to generalize this support.
authors: Service de chirurgie oncologique, institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
authors: E
authors: E
authors: Furet
authors: E
authors: E
authors: Chéreau
authors: E
authors: E
authors: Lambaudie
authors: M
authors: M
authors: Bannier
authors: G
authors: G
authors: Houvenaeghel
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006358:Hot Temperature; D006801:Humans; D007431:Intraoperative Complications / Q000453:epidemiology; D009017:Morbidity; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D010537:Peritoneum / Q000187:drug effects; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Cancer de l’ovaire; Chimiohyperthermie intrapéritonéale; Chirurgie; Hyperthermic intraperitoneal chemotherapy; Morbidity; Morbidité; Ovarian cancer; Recurrence; Récidive; Surgery